GastroCE
CME

Vaccinations and IBD: Special Considerations and Preventive Measures to Improve Patient Outcomes

Author(s)/Faculty: Francis A. Farraye, MD, MSc; Gary R. Lichtenstein, MD; David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Release Date: 3/12/2018Expiration Date: 3/11/2019
Credit Type: CMENumber of Credits: 0.5
Content Type: LectureProvider:
The treatment of inflammatory bowel disease (IBD) has been revolutionized by using immunomodulatory agents that are effective in controlling disease activity. However, these agents also cause an increased risk of new infections or reactivation of latent infections. Immunosuppressed patients have an increased risk of severe viral infections, and national and international vaccination guidelines have been developed to decrease the mortality risk associated with these infections. In addition, the course of IBD and its treatment may vary over time, and a patient’s immunocompromised status may hamper the efficacy and/or eligibility to receive certain vaccines. This CME program will educate health care providers about opportunistic infections in immunocompromised patients and the associated risk factors in patients with IBD. Proper screening tests for infectious diseases will be discussed, as well as the vaccination schedules before and/or during therapy with immunomodulators based on recently issued guidelines from the American College of Gastroenterology for preventive immunization in patients with IBD.